STOCK TITAN

Pfizer Inc. - PFE STOCK NEWS

Welcome to our dedicated news page for Pfizer (Ticker: PFE), a resource for investors and traders seeking the latest updates and insights on Pfizer.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Pfizer's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Pfizer's position in the market.

Rhea-AI Summary
Pfizer's LITFULO receives marketing authorization in Europe to treat severe alopecia areata in individuals 12 years and older.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.04%
Tags
none
-
Rhea-AI Summary
Pfizer Inc. to provide an update on Q3 2023 results in conference call on October 31, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.26%
Tags
conferences
-
Rhea-AI Summary
EMA validates Astellas Pharma's Type II variation for XTANDI® (enzalutamide) in the treatment of non-metastatic hormone-sensitive prostate cancer with high-risk biochemical recurrence, potentially expanding its use in the EU market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.4%
Tags
none
Rhea-AI Summary
Pfizer Inc. invites investors and the general public to view and listen to a webcast of a discussion with David Denton, CFO, at the J.P. Morgan 14th Annual U.S. All Stars Conference on Sep 18. The transcript and webcast replay will be available on their website within 24 hours and accessible for at least 90 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.62%
Tags
conferences
-
Rhea-AI Summary
FDA approves Pfizer and BioNTech's Omicron XBB.1.5-adapted COVID-19 vaccine for individuals 12 years and older
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.81%
Tags
fda approval covid-19
-
Rhea-AI Summary
Pfizer invites investors and the public to a webcast of a discussion at the Morgan Stanley Global Healthcare Conference on September 11, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.12%
Tags
conferences
Rhea-AI Summary
Pfizer Inc. invites investors and the general public to view and listen to two upcoming webcasts of Pfizer discussions at healthcare conferences. Transcripts and webcast replays will be available on their website within 24 hours and accessible for at least 90 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.69%
Tags
none
-
Rhea-AI Summary
Switching from Eliquis (apixaban) to rivaroxaban in Non-Valvular Atrial Fibrillation (NVAF) patients was associated with a higher risk of stroke/systemic embolism (S/SE) and major bleeding (MB) than those who continued Eliquis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.31%
Tags
none
-
Rhea-AI Summary
Pfizer's ABRYSVO RSV vaccine receives marketing authorization in the EU for infants and older adults.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.36%
Tags
none
Rhea-AI Summary
Everest Medicines announces interim results for H1 2023, with successful launch of Xerava® in China and expected approvals for Nefecon® in China and Singapore. Expenses reduced by over a third compared to last year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.36%
Tags
none
Pfizer Inc.

NYSE:PFE

PFE Rankings

PFE Stock Data

146.43B
5.64B
0.05%
69.93%
1.15%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Palo Alto

About PFE

Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered at The Spiral in Manhattan, New York City. The company was established in 1849 in New York by two German entrepreneurs, Charles Pfizer and his cousin Charles F. Erhart.